The precision cancer therapy developer, based on research from several universities, floated at the top of an upsized range and saw its price continue to rise post-IPO.

The precision cancer therapy developer, which counts Sanofi as a significant shareholder, floated at the top of an upsized range and saw its price continue to rise post-IPO.

Goldman Sachs led a round that valued Flywire at more than $1bn as the digital payment processor acquired American Express-backed Simplee.

Legal & General increased its stake in the charging infrastructure operator to 23% while EDF purchased a majority share in a $130m deal.

Comcast Ventures has exited Hollar in an acquisition by Five Below, which is reportedly set to shut down the budget e-commerce platform.

Less than three years after raising money at a valuation of up to $1bn, Essential is shutting down after low sales of its alternative Android smartphone.

Biopsy verification technology developer Strand Diagnostics had raised $7.5m of a commitment from Nantworks originally slated to reach $30m.

The genomic drug developer, spun out of Harvard University, has completed its initial public offering, boosting its size from $180m to $207m.

The genomic drug developer, which counts GV as an investor, has completed its initial public offering, boosting its size from $180m to $207m.

Infosys has agreed to pay $250m for sales services provider Simplus, which had raised more than $40m in funding from backers including Salesforce Ventures.